Globeimmune Inc represents values of innovation, collaboration, and a commitment to improving patient outcomes. With a focus on developing targeted immunotherapies, the company aims to revolutionize the treatment of diseases. Globeimmune Inc prioritizes cutting-edge research and partnerships with leading organizations to advance their pipeline of innovative therapies. Their corporate philosophy revolves around scientific excellence, integrity, and a patient-centric approach. By leveraging their expertise, Globeimmune Inc strives to address unmet medical needs and provide hope for patients worldwide. Through their dedication to these values, Globeimmune Inc continues to push the boundaries of medical science and positively impact the healthcare industry.

Globeimmune Inc is primarily present in the United States, as it is a biopharmaceutical company headquartered in Louisville, Colorado.

Globeimmune Inc has achieved several significant milestones. The company successfully completed a Phase 1 clinical trial for its lead product candidate, GI-6301, which showed promising results in patients with metastatic pancreatic ductal adenocarcinoma. Additionally, Globeimmune signed a strategic collaboration agreement with Gilead Sciences Inc to develop a therapeutic vaccine for chronic hepatitis B virus infection. Furthermore, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for GI-6207, its investigational immunotherapy for the treatment of non-resectable pancreatic cancer. Overall, Globeimmune Inc has made notable advancements in the field of immunotherapy and continues to strive towards developing innovative treatments for various diseases.

Globeimmune Inc is a biotechnology company founded in 2009. It specializes in developing immunotherapies and vaccines for the treatment of various diseases, including cancer and infectious diseases. The company has a rich background in biomedical research and has successfully advanced several product candidates into clinical trials. Globeimmune Inc is known for its innovative approach in leveraging the body's immune system to fight diseases. With its dedicated team of scientists and strategic collaborations, the company aims to revolutionize the field of immunotherapy. Globeimmune Inc has gained recognition in the biotech industry for its cutting-edge technologies and commitment to improving patients' lives.

Globeimmune Inc faces competition from various companies in the market. Some of the main competitors of Globeimmune Inc include Aduro Biotech, BioNTech SE, Celgene Corporation, Gilead Sciences, and Merck & Co. These companies compete in the field of biotechnology and immunotherapy, offering innovative solutions in the development of drugs and vaccines. Their products and technologies pose significant competition for Globeimmune Inc., pushing the company to continually innovate and differentiate itself in the market.

Globeimmune Inc is primarily active in the biotechnology industry. As a biotech company, Globeimmune focuses on developing immunotherapies to treat cancer and infectious diseases. Through innovative research and development, Globeimmune aims to provide effective solutions to improve patient outcomes in these critical areas. With a strong focus on leveraging the power of the immune system, Globeimmune is committed to advancing medical science and revolutionizing the treatment landscape.

The business model of Globeimmune Inc revolves around the development of novel immunotherapies for treating cancer and infectious diseases. The company focuses on utilizing its proprietary Tarmogen technology platform, which helps in activating the immune system to recognize and destroy diseased cells. By harnessing the power of the immune system, Globeimmune aims to provide more effective and targeted treatment options for patients. With a strong emphasis on research and development, the company strives to bring innovative therapies to market that can potentially address unmet medical needs. Globeimmune Inc is committed to transforming the way diseases are treated through its immunotherapy advancements.

Pašreizējais KGV Globeimmune nevar tikt aprēķināts.

KUV šobrīd Globeimmune nevar aprēķināt.

AlleAktien kvalitātes vērtējums Globeimmune ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Globeimmune.

Pašlaik peļņa Globeimmune nevar tikt aprēķināta.

GlobeImmune Inc is a biotechnology company specialized in the development of immunotherapy products for cancer and infectious diseases. The company is headquartered in Louisville, Colorado, and has subsidiaries in Germany and Switzerland. The business strategy of GlobeImmune is divided into two main divisions: immunotherapy products for cancer and infectious diseases, and biotechnological research services. In the field of immunotherapy, GlobeImmune develops drugs that enable the patient's immune system to fight specific tumor cells or infectious agents. In this division, the company has several product candidates in the pipeline, currently being tested in clinical development. These include both monoclonal antibodies and antigens specifically targeting cancer cells or virus infections. GlobeImmune's flagship product is the immunotherapeutic GI-6301, being tested in a phase 2 cancer study for the treatment of metastatic pancreatic cancer. The company is also working on a monoclonal antibody for the treatment of prostate cancer, GI-101A, as well as an antigen-based therapeutic candidate for the treatment of lung cancer, GI-4000. In the field of biotechnological research, GlobeImmune offers scientific services to assist other companies in the development of biological products. These services include antigen identification and the development of immunotherapy platforms and technologies. GlobeImmune has a leading position in the production of peptides, antigens, and recombinant protein products, particularly in the manufacturing of Chimeric Antigen Receptor (CAR) therapies. To successfully implement its business model and business strategy, GlobeImmune has various partnerships and collaborations with other companies in the biotechnology industry, pharmaceutical, and diagnostic sectors. The collaborations aim to combine existing resources and accelerate the development of new products. GlobeImmune has contracts with various academic institutions, including the National Cancer Institute and Duke University Medical Center, to advance research. Overall, GlobeImmune Inc is an emerging biotechnology company focused on immunotherapy, offering a wide range of products and services. The company focuses on personalized medicine and relies on innovative technologies to achieve results that improve patients' lives. GlobeImmune pursues a scientifically-based and goal-oriented strategy to advance the development of promising therapeutic approaches and achieve a leading position in the biotechnology industry.

Globeimmune izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Globeimmune vai uzņēmums nedod dividendes.

Globeimmune ISIN ir US37957B1008.

Globeimmune WKN ir A1J41J.

Globeimmune simbols ir GBIM.

Pēdējo 12 mēnešu laikā Globeimmune maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Globeimmune plāno maksāt dividendes 0 USD apmērā.

Globeimmune pašreizējā dividendu rentabilitāte ir .

Globeimmune maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Globeimmune pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Globeimmune tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Globeimmune apmērā 0 USD, kas tika izmaksāta 13.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 13.08.2024..

Pēdējās dividendes izmaksa notika 13.08.2024..

Gadā 2023, Globeimmune izmaksāja 0 USD dividendes.

Globeimmune dividendes tiek izmaksātas USD.